|
G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions increases expression
|
ISO EXP
|
3',4',7-trihydroxyisoflavone inhibits the reaction [Epirubicin results in increased expression of ABCB1 mRNA]; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of ABCB1 mRNA; [Epirubicin co-treated with chrysophsin] results in increased expression of ABCB1 mRNA; ABCB1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; formononetin inhibits the reaction [Epirubicin results in increased expression of ABCB1 mRNA] Epirubicin analog results in increased expression of ABCB1 mRNA; Epirubicin results in increased expression of ABCB1 mRNA [Diethylnitrosamine co-treated with Epirubicin] results in increased expression of ABCB1 protein
|
CTD |
PMID:11818250 PMID:12576456 PMID:22914566 PMID:23867903 PMID:26335193 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
multiple interactions decreases response to substance increases expression
|
ISO
|
3',4',7-trihydroxyisoflavone inhibits the reaction [Epirubicin results in increased expression of ABCC1 mRNA]; ABCC1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; formononetin inhibits the reaction [Epirubicin results in increased expression of ABCC1 mRNA] ABCC1 protein results in decreased susceptibility to Epirubicin Epirubicin analog results in increased expression of ABCC1 mRNA; Epirubicin results in increased expression of ABCC1 mRNA
|
CTD |
PMID:7954421 PMID:12576456 PMID:12657726 PMID:22914566 PMID:23867903 PMID:26335193 More...
|
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions increases expression
|
ISO
|
3',4',7-trihydroxyisoflavone inhibits the reaction [Epirubicin results in increased expression of ABCC2 mRNA]; formononetin inhibits the reaction [Epirubicin results in increased expression of ABCC2 mRNA] Epirubicin analog results in increased expression of ABCC2 mRNA; Epirubicin results in increased expression of ABCC2 mRNA
|
CTD |
PMID:22914566 PMID:23867903 PMID:26335193 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions decreases response to substance
|
ISO
|
ABCG2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] ABCG2 protein results in decreased susceptibility to Epirubicin
|
CTD |
PMID:10606239 PMID:12576456 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:87,745,319...87,802,409
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions decreases phosphorylation increases phosphorylation
|
ISO EXP
|
paeonol inhibits the reaction [Epirubicin results in decreased phosphorylation of AKT1 protein] Epirubicin results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Epirubicin results in increased phosphorylation of AKT1 protein]; paeonol inhibits the reaction [Epirubicin results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:26646421 PMID:29505745 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G
|
Ar
|
androgen receptor
|
multiple interactions
|
ISO
|
Epirubicin binds to and results in decreased activity of AR protein; Epirubicin binds to and results in increased activity of AR protein
|
CTD |
PMID:25752796 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G
|
Atg5
|
autophagy related 5
|
decreases expression multiple interactions
|
EXP
|
Epirubicin results in decreased expression of ATG5 protein paeonol inhibits the reaction [Epirubicin results in decreased expression of ATG5 protein]; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of ATG5 protein]
|
CTD |
PMID:29505745 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209
|
|
G
|
Atg7
|
autophagy related 7
|
multiple interactions
|
ISO
|
[baicalein 5,6,7-trimethyl ether co-treated with Epirubicin] results in increased expression of ATG7 mRNA
|
CTD |
PMID:38040128 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions increases expression
|
ISO
|
3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of BAX mRNA]; [baicalein 5,6,7-trimethyl ether co-treated with Epirubicin] results in increased expression of BAX protein; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of BAX mRNA; chrysophsin promotes the reaction [Epirubicin results in increased expression of BAX mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of BAX mRNA]; Epirubicin promotes the reaction [chrysophsin results in increased expression of BAX mRNA]; formononetin promotes the reaction [Epirubicin results in increased expression of BAX mRNA] Epirubicin results in increased expression of BAX protein paeonol inhibits the reaction [Epirubicin results in increased expression of BAX protein]
|
CTD |
PMID:22914566 PMID:23867903 PMID:26335193 PMID:26646421 PMID:29505745 PMID:38040128 More...
|
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
increases expression multiple interactions decreases expression
|
ISO
|
Epirubicin analog results in increased expression of BCL2 mRNA; Epirubicin results in increased expression of BCL2 mRNA [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of BCL2 mRNA; [Epirubicin co-treated with chrysophsin] results in increased expression of BCL2 mRNA Epirubicin results in decreased expression of BCL2 protein paeonol inhibits the reaction [Epirubicin results in decreased expression of BCL2 protein]
|
CTD |
PMID:14503796 PMID:23867903 PMID:26335193 PMID:26646421 PMID:29505745 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G
|
Becn1
|
beclin 1
|
decreases expression multiple interactions
|
EXP ISO
|
Epirubicin results in decreased expression of BECN1 protein paeonol inhibits the reaction [Epirubicin results in decreased expression of BECN1 protein]; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of BECN1 protein] [baicalein 5,6,7-trimethyl ether co-treated with Epirubicin] results in increased expression of BECN1 protein
|
CTD |
PMID:29505745 PMID:38040128 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
decreases response to substance increases expression multiple interactions
|
ISO
|
BIRC5 protein results in decreased susceptibility to Epirubicin Epirubicin results in increased expression of BIRC5 protein [Gossypol results in decreased phosphorylation of EIF4EBP1 protein] inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]; Gossypol inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]; MK 2206 inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]
|
CTD |
PMID:16188142 PMID:35872041 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380
|
|
G
|
Birc6
|
baculoviral IAP repeat-containing 6
|
decreases response to substance
|
ISO
|
BIRC6 results in decreased susceptibility to Epirubicin
|
CTD |
PMID:21542283 |
|
NCBI chr 6:26,474,843...26,668,275
Ensembl chr 6:20,722,922...20,916,434
|
|
G
|
Casp1
|
caspase 1
|
increases response to substance
|
ISO
|
CASP1 results in increased susceptibility to Epirubicin
|
CTD |
PMID:9491796 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G
|
Casp3
|
caspase 3
|
multiple interactions increases activity increases expression increases cleavage
|
ISO
|
3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of CASP3 mRNA]; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of CASP3 mRNA; chrysophsin promotes the reaction [Epirubicin results in increased expression of CASP3 mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased activity of CASP3 protein]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of CASP3 mRNA]; Epirubicin promotes the reaction [chrysophsin results in increased expression of CASP3 mRNA]; Epirubicin promotes the reaction [formononetin results in increased activity of CASP3 protein]; Epirubicin promotes the reaction [formononetin results in increased expression of CASP3 mRNA]; Epirubicin results in increased activity of and affects the localization of CASP3 protein; formononetin promotes the reaction [Epirubicin results in increased activity of CASP3 protein]; formononetin promotes the reaction [Epirubicin results in increased expression of CASP3 mRNA] Epirubicin results in increased cleavage of CASP3 protein paeonol inhibits the reaction [Epirubicin results in increased cleavage of CASP3 protein]
|
CTD |
PMID:14503796 PMID:15996160 PMID:22914566 PMID:23867903 PMID:26335193 PMID:26646421 PMID:29505745 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO
|
Epirubicin promotes the reaction [formononetin results in increased activity of CASP8 protein]; Epirubicin promotes the reaction [formononetin results in increased expression of CASP8 mRNA]
|
CTD |
PMID:23867903 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G
|
Casp9
|
caspase 9
|
multiple interactions increases activity increases expression
|
ISO
|
3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of CASP9 mRNA]; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of CASP9 mRNA; chrysophsin promotes the reaction [Epirubicin results in increased expression of CASP9 mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased activity of CASP9 protein]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of CASP9 mRNA]; Epirubicin promotes the reaction [chrysophsin results in increased expression of CASP9 mRNA]; Epirubicin promotes the reaction [formononetin results in increased activity of CASP9 protein]; Epirubicin promotes the reaction [formononetin results in increased expression of CASP9 mRNA]; formononetin promotes the reaction [Epirubicin results in increased activity of CASP9 protein]; formononetin promotes the reaction [Epirubicin results in increased expression of CASP9 mRNA]
|
CTD |
PMID:22914566 PMID:23867903 PMID:26335193 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G
|
Cat
|
catalase
|
decreases activity multiple interactions
|
ISO EXP
|
Epirubicin results in decreased activity of CAT protein paeonol inhibits the reaction [Epirubicin results in decreased activity of CAT protein] 3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in decreased activity of CAT protein]
|
CTD |
PMID:26646421 PMID:36822302 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G
|
Ccn2
|
cellular communication network factor 2
|
increases expression multiple interactions
|
ISO
|
Epirubicin results in increased expression of CCN2 mRNA Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA]
|
CTD |
PMID:22712078 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G
|
Dpyd
|
dihydropyrimidine dehydrogenase
|
multiple interactions
|
ISO
|
DPYD protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin]
|
CTD |
PMID:16646564 |
|
NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:206,609,122...207,474,982
|
|
G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions
|
ISO
|
EGFR protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]
|
CTD |
PMID:18768436 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
multiple interactions increases phosphorylation
|
ISO
|
[Gossypol results in decreased phosphorylation of EIF4EBP1 protein] inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]; Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of EIF4EBP1 protein]; MK 2206 inhibits the reaction [Epirubicin results in increased phosphorylation of EIF4EBP1 protein]
|
CTD |
PMID:35872041 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G
|
Erbb2
|
erb-b2 receptor tyrosine kinase 2
|
multiple interactions
|
ISO
|
ERBB2 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16446318 PMID:16682728 PMID:18768436 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G
|
Erbb3
|
erb-b2 receptor tyrosine kinase 3
|
multiple interactions
|
ISO
|
ERBB3 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]
|
CTD |
PMID:18768436 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G
|
Esr1
|
estrogen receptor 1
|
multiple interactions
|
ISO
|
Epirubicin binds to and results in decreased activity of ESR1 protein
|
CTD |
PMID:25752796 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G
|
Esr2
|
estrogen receptor 2
|
multiple interactions
|
ISO
|
Epirubicin binds to and results in decreased activity of ESR2 protein
|
CTD |
PMID:25752796 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G
|
Fas
|
Fas cell surface death receptor
|
increases expression
|
EXP
|
Epirubicin results in increased expression of FAS protein
|
CTD |
PMID:19429229 |
|
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
|
|
G
|
Faslg
|
Fas ligand
|
increases expression
|
EXP
|
Epirubicin results in increased expression of FASLG protein; Epirubicin results in increased expression of FASLG protein modified form
|
CTD |
PMID:19429229 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G
|
Fkbpl
|
FKBP prolyl isomerase like
|
increases expression
|
ISO
|
Epirubicin results in increased expression of FKBPL mRNA
|
CTD |
PMID:14503796 |
|
NCBI chr20:4,099,845...4,101,315
Ensembl chr20:4,099,806...4,101,368
|
|
G
|
Fshb
|
follicle stimulating hormone subunit beta
|
decreases expression multiple interactions
|
EXP
|
Epirubicin results in decreased expression of FSHB protein 3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in decreased expression of FSHB protein]
|
CTD |
PMID:36822302 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G
|
Il2
|
interleukin 2
|
increases expression multiple interactions
|
ISO
|
Epirubicin results in increased expression of IL2 mRNA; Epirubicin results in increased expression of IL2 protein paeonol inhibits the reaction [Epirubicin results in increased expression of IL2 mRNA]; paeonol inhibits the reaction [Epirubicin results in increased expression of IL2 protein]
|
CTD |
PMID:26646421 PMID:29505745 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G
|
Il6
|
interleukin 6
|
increases expression multiple interactions
|
ISO
|
Epirubicin results in increased expression of IL6 protein paeonol inhibits the reaction [Epirubicin results in increased expression of IL6 mRNA]
|
CTD |
PMID:17914082 PMID:19060235 PMID:26646421 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G
|
Il6r
|
interleukin 6 receptor
|
increases expression
|
ISO
|
Epirubicin results in increased expression of IL6R protein
|
CTD |
PMID:19060235 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation
|
ISO
|
Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:35872041 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation
|
ISO
|
Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:35872041 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G
|
Marveld1
|
MARVEL domain containing 1
|
increases response to substance
|
ISO
|
MARVELD1 protein results in increased susceptibility to Epirubicin
|
CTD |
PMID:31205918 |
|
NCBI chr 1:240,954,050...240,958,101
Ensembl chr 1:240,954,452...240,958,384
|
|
G
|
Mir1
|
microRNA 1
|
decreases expression multiple interactions
|
EXP
|
Epirubicin results in decreased expression of MIR1 mRNA paeonol inhibits the reaction [Epirubicin results in decreased expression of MIR1 mRNA]
|
CTD |
PMID:29505745 |
|
NCBI chr18:1,887,537...1,887,623
|
|
G
|
Mpo
|
myeloperoxidase
|
increases activity multiple interactions
|
EXP
|
Epirubicin results in increased activity of MPO protein 3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in increased activity of MPO protein]
|
CTD |
PMID:36822302 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G
|
Mtor
|
mechanistic target of rapamycin kinase
|
increases phosphorylation multiple interactions
|
EXP
|
Epirubicin results in increased phosphorylation of MTOR protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Epirubicin results in increased phosphorylation of MTOR protein]; paeonol inhibits the reaction [Epirubicin results in increased phosphorylation of MTOR protein]
|
CTD |
PMID:29505745 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G
|
Ncoa2
|
nuclear receptor coactivator 2
|
multiple interactions
|
ISO
|
Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]
|
CTD |
PMID:25257666 |
|
NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:5,835,706...6,067,451
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
EXP
|
Epirubicin results in decreased expression of and results in increased phosphorylation of NFKBIA protein; paeonol inhibits the reaction [Epirubicin results in decreased expression of and results in increased phosphorylation of NFKBIA protein]; prolinedithiocarbamate inhibits the reaction [Epirubicin results in decreased expression of and results in increased phosphorylation of NFKBIA protein]
|
CTD |
PMID:29505745 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G
|
Nppa
|
natriuretic peptide A
|
increases expression
|
ISO
|
Epirubicin results in increased expression of NPPA protein
|
CTD |
PMID:1831809 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
ISO
|
Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Epirubicin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]
|
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions
|
ISO
|
Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]
|
CTD |
PMID:29356861 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
increases cleavage multiple interactions
|
ISO
|
Epirubicin results in increased cleavage of PARP1 protein paeonol inhibits the reaction [Epirubicin results in increased cleavage of PARP1 protein] [Gossypol co-treated with Epirubicin] results in increased cleavage of PARP1 protein
|
CTD |
PMID:26646421 PMID:35872041 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G
|
Pgr
|
progesterone receptor
|
multiple interactions
|
ISO
|
Epirubicin binds to and results in decreased activity of PGR protein
|
CTD |
PMID:25752796 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:6,072,673...6,131,344
|
|
G
|
Phlda2
|
pleckstrin homology-like domain, family A, member 2
|
increases response to substance
|
ISO
|
PHLDA2 results in increased susceptibility to Epirubicin
|
CTD |
PMID:22021909 |
|
NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836
|
|
G
|
Pml
|
PML nuclear body scaffold
|
affects mutagenesis
|
ISO
|
Epirubicin affects the mutagenesis of PML gene
|
CTD |
PMID:19884644 |
|
NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:58,628,837...58,658,971
|
|
G
|
Prl
|
prolactin
|
increases expression multiple interactions
|
EXP
|
Epirubicin results in increased expression of PRL protein 3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in increased expression of PRL protein]
|
CTD |
PMID:36822302 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G
|
Rara
|
retinoic acid receptor, alpha
|
affects mutagenesis
|
ISO
|
Epirubicin affects the mutagenesis of RARA gene
|
CTD |
PMID:19884644 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions increases phosphorylation
|
EXP
|
paeonol inhibits the reaction [Epirubicin results in increased phosphorylation of RELA protein]; prolinedithiocarbamate inhibits the reaction [Epirubicin results in increased phosphorylation of RELA protein]
|
CTD |
PMID:29505745 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G
|
Rps6kb1
|
ribosomal protein S6 kinase B1
|
multiple interactions increases phosphorylation
|
ISO
|
Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of RPS6KB1 protein]; MK 2206 inhibits the reaction [Epirubicin results in increased phosphorylation of RPS6KB1 protein]
|
CTD |
PMID:35872041 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908
|
|
G
|
Sod2
|
superoxide dismutase 2
|
affects response to substance
|
ISO
|
SOD2 protein affects the susceptibility to Epirubicin
|
CTD |
PMID:9569045 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:47,636,528...47,645,189
|
|
G
|
Sqstm1
|
sequestosome 1
|
multiple interactions increases expression
|
EXP
|
paeonol inhibits the reaction [Epirubicin results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [Epirubicin results in increased expression of SQSTM1 protein]
|
CTD |
PMID:29505745 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
ISO
|
[baicalein 5,6,7-trimethyl ether co-treated with Epirubicin] results in decreased expression of TGFB1 mRNA
|
CTD |
PMID:38040128 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G
|
Thra
|
thyroid hormone receptor alpha
|
multiple interactions
|
ISO
|
Epirubicin binds to and results in decreased activity of THRA protein
|
CTD |
PMID:25752796 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G
|
Thrb
|
thyroid hormone receptor beta
|
multiple interactions
|
ISO
|
Epirubicin binds to and results in decreased activity of THRB protein
|
CTD |
PMID:25752796 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G
|
Tnf
|
tumor necrosis factor
|
increases expression multiple interactions
|
ISO
|
Epirubicin results in increased expression of TNF mRNA; Epirubicin results in increased expression of TNF protein paeonol inhibits the reaction [Epirubicin results in increased expression of TNF mRNA]; paeonol inhibits the reaction [Epirubicin results in increased expression of TNF protein]
|
CTD |
PMID:26646421 PMID:29505745 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
multiple interactions
|
ISO
|
TOP2A protein affects the susceptibility to [Cyclophosphamide co-treated with Epirubicin co-treated with Fluorouracil]; TOP2A protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]
|
CTD |
PMID:16682728 PMID:18465341 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:83,945,735...83,976,874
|
|
G
|
Tp53
|
tumor protein p53
|
multiple interactions increases expression
|
ISO
|
3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of TP53 mRNA]; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of TP53 mRNA; chrysophsin promotes the reaction [Epirubicin results in increased expression of TP53 mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of TP53 mRNA]; Epirubicin promotes the reaction [chrysophsin results in increased expression of TP53 mRNA]
|
CTD |
PMID:22914566 PMID:26335193 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G
|
Tshb
|
thyroid stimulating hormone subunit beta
|
multiple interactions decreases expression
|
EXP
|
3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in decreased expression of TSHB protein]
|
CTD |
PMID:36822302 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G
|
Tymp
|
thymidine phosphorylase
|
multiple interactions
|
ISO
|
[Epirubicin co-treated with Cyclophosphamide] results in increased expression of TYMP protein
|
CTD |
PMID:15150550 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
G
|
Vegfc
|
vascular endothelial growth factor C
|
multiple interactions
|
ISO
|
VEGFC mRNA results in increased susceptibility to [Paclitaxel co-treated with Epirubicin co-treated with CMF regimen]
|
CTD |
PMID:23146280 |
|
NCBI chr16:44,445,293...44,560,887
Ensembl chr16:37,712,262...37,827,848
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
increases activity multiple interactions
|
EXP
|
Epirubicin results in increased activity of XDH protein 3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in increased activity of XDH protein]
|
CTD |
PMID:36822302 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|